Edgewise Therapeutics, Inc.
EWTX
Clasificación en acciones
#4058
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Precio por acción
$37.15
Última sincronización: 2026-10-16
Capitalización bursátil
$4.00B
Cambio (1 día)
-2.75%
Cambio (1 año)
146.68%
País
US
Comercio Edgewise Therapeutics, Inc. (EWTX)
Categoría
Healthcare
Historial de dividendos de Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. (símbolo bursátil: EWTX) realizó un total de 0 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: 0.00
Rentabilidad por dividendo (TTM): 0
La suma de todos los dividendos (ajustados por splits de acciones) es: 0.00
Rentabilidad por dividendo (TTM): 0
Pagos de dividendos de Edgewise Therapeutics, Inc. (EWTX) desde 2026 hasta 2026
Pagos anuales de dividendos
| Año | Dividendo (ajustado por splits de acciones) | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Lista de todos los pagos de dividendos
| Año | Dividendo | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Pagos de dividendos de empresas similares o competidoras
| Empresa | Número de pagos de dividendos | País |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
